Safety and tolerability of andecaliximab as monotherapy and in combination with an anti-PD-1 antibody in Japanese patients with gastric or gastroesophageal junction adenocarcinoma: a phase 1b study.

Akie Kimura YoshikawaKensei YamaguchiKei MuroAtsuo TakashimaTakashi IchimuraDaisuke SakaiShigenori KadowakiKeisho ChinToshihiro KudoSeiichiro MitaniShigehisa KitanoDung ThaiMarianna ZavodovskayaJieJane LiuNarikazu BokuTaroh Satoh

Published in: Journal for immunotherapy of cancer (2022)

The andecaliximab-nivolumab combination demonstrated a manageable safety profile and promising clinical activity in patients with advanced gastric adenocarcinoma.NCT02862535.

Keyphrases

squamous cell carcinoma
open label
combination therapy
randomized controlled trial
clinical trial
study protocol